Article Text

other Versions

Download PDFPDF
MHRA issues two updates on fluoroquinolone safety

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Key learning points

  • The Medicines and Healthcare products Regulatory Agency (MHRA) has published two safety updates on fluoroquinolone antibiotics.

  • The MHRA continues to receive reports of adverse events with fluoroquinolones including one death by suicide thought to be related to ciprofloxacin.

  • Fluoroquinolones should not be prescribed for non-severe or self-limiting infections and used cautiously in people in at-risk groups.

  • All patients, but especially those with existing mental health issues, should be made aware of the risk of new or worsening psychiatric symptoms associated with fluoroquinolones.

The Medicines and Healthcare products Regulatory Agency has issued two updates about serious safety issues associated with systemic fluoroquinolone antibiotics.1 2

Overview

In 2019, restrictions on the use of fluoroquinolone antibiotics were introduced because …

View Full Text

Footnotes

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.